<p>Aytu BioScience（AYTU）召开了第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识你的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 ETF AI 分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 ETF AI 分析师对你关注的 ETF 所揭示的见解。</li>
</ul>
<p>Aytu BioScience 最近的财报电话会议反映出公司在把握增长机会与应对挑战之间的平衡。整体情绪较为积极，重点关注即将推出的产品和管理现有投资组合的挑战。ADHD 投资组合的表现和 EXXUA 的推出进展被强调为增长和战略关注的领域，而某些细分市场的下滑和监管担忧则被视为挑战。</p>
<h2>ADHD 投资组合的积极收入表现</h2>
<p>ADHD 投资组合表现强劲，净收入同比增长约 10%，不包括来自去年的一次性折扣收益。这一增长展示了该投资组合在预期中的强劲表现，并突显了 Aytu BioScience 对该细分市场的战略关注。</p>
<h2>EXXUA 推出进展</h2>
<p>EXXUA 的推出预计将在 2025 年年底前完成，关键意见领袖（KOL）参与、销售团队培训和产品定位方面取得了显著进展。这些发展强调了公司确保 EXXUA 成功进入市场的承诺。</p>
<h2>EXXUA 的专利延长</h2>
<p>Aytu BioScience 成功将 EXXUA 的使用方法专利延长至 2030 年 9 月，增强了其知识产权保护。这一延长是保护产品市场潜力和竞争优势的战略举措。</p>
<h2>强劲的现金状况</h2>
<p>公司报告称现金状况良好，截至本季度末现金及现金等价物总额为 3260 万美元，较上季度的 3100 万美元有所增加。这一现金储备的增加为 Aytu BioScience 提供了坚实的财务基础，以支持其战略举措。</p>
<h2>儿科投资组合收入下降</h2>
<p>儿科投资组合的收入下降，从去年的 130 万美元降至 70 万美元。这一下降归因于生产延迟和对市场营销工作的重视程度降低，给公司带来了挑战。</p>
<h2>毛利率下降</h2>
<p>Aytu BioScience 报告称毛利率从去年的 72% 下降至 66%。在排除一次性折扣后，毛利率调整为 65%。这一下降表明公司需要关注成本管理和效率问题。</p>
<h2>对氟化物产品的监管担忧</h2>
<p>FDA 就含氟药物发布了通知，尽管预计影响有限。公司本季度仅报告了 30 万美元的氟化物产品收入，表明财务风险较小。</p>
<h2>前瞻性指导</h2>
<p>展望未来，Aytu BioScience 提供了前瞻性指导，预计 2026 财年第一季度净收入为 1390 万美元。ADHD 投资组合的净收入较去年增长 10%，不包括一次性折扣收益。EXXUA 的推出仍按计划在 2025 年年底前进行，产品制造、销售团队培训和市场营销策略持续取得进展。公司预计 2026 财年的运营支出为 5000 万美元，其中包括对 EXXUA 推出的 1000 万美元投资。Aytu 预计实现季度净收入 1730 万美元将使其达到盈亏平衡，强调了他们对 EXXUA 作为治疗重度抑郁症的变革性产品潜力的信心。</p>
<p>总之，Aytu BioScience 的财报电话会议突显了公司通过战略产品推出和管理现有挑战来专注于增长。积极的情绪源于 ADHD 投资组合的强劲表现和 EXXUA 推出的进展，同时也承认了某些细分市场的下滑和监管担忧。公司的前瞻性指导反映了对其战略举措的信心以及未来增长的潜力。</p>

AYTU

<p>Aytu BioScience 的第一季度财报电话会议强调了增长机会和挑战。关键点包括 ADHD 产品组合收入增长 10%，预计到 2025 年底 EXXUA 的推出进展，以及 EXXUA 专利延长至 2030 年。公司报告了 3260 万美元的强劲现金储备。挑战包括儿科产品组合收入下降、毛利率下降，以及对氟化物产品的监管担忧。前瞻性指引预计 2026 财年第一季度净收入为 1390 万美元，运营支出为 5000 万美元</p>

<p>Aytu BioScience ((AYTU)) has held its Q1 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Aytu BioScience（AYTU）召开了第一季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识你的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 ETF AI 分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 ETF AI 分析师对你关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>Aytu BioScience’s recent earnings call reflects a company navigating both growth opportunities and challenges. The sentiment was largely positive, focusing on upcoming product launches and managing existing portfolio challenges. The performance of the ADHD portfolio and progress towards the EXXUA launch were highlighted as areas of growth and strategic focus, while declines in certain segments and regulatory concerns were noted as challenges.</p>
<div class="lb-trans"><p>Aytu BioScience 最近的财报电话会议反映出公司在把握增长机会与应对挑战之间的平衡。整体情绪较为积极，重点关注即将推出的产品和管理现有投资组合的挑战。ADHD 投资组合的表现和 EXXUA 的推出进展被强调为增长和战略关注的领域，而某些细分市场的下滑和监管担忧则被视为挑战。</p>
</div><h2>Positive Revenue Performance in ADHD Portfolio</h2>
<div class="lb-trans"><h2>ADHD 投资组合的积极收入表现</h2>
</div><p>The ADHD portfolio demonstrated a robust performance with net revenue increasing by approximately 10% year-over-year, excluding a one-time rebate benefit from the previous year. This growth showcases the portfolio’s strong performance against expectations and highlights Aytu BioScience’s strategic focus on this segment.</p>
<div class="lb-trans"><p>ADHD 投资组合表现强劲，净收入同比增长约 10%，不包括来自去年的一次性折扣收益。这一增长展示了该投资组合在预期中的强劲表现，并突显了 Aytu BioScience 对该细分市场的战略关注。</p>
</div><h2>EXXUA Launch Progress</h2>
<div class="lb-trans"><h2>EXXUA 推出进展</h2>
</div><p>The EXXUA launch is on track for the end of calendar 2025, with significant advancements in key opinion leader (KOL) engagement, sales force training, and product positioning. These developments underscore the company’s commitment to ensuring a successful market entry for EXXUA.</p>
<div class="lb-trans"><p>EXXUA 的推出预计将在 2025 年年底前完成，关键意见领袖（KOL）参与、销售团队培训和产品定位方面取得了显著进展。这些发展强调了公司确保 EXXUA 成功进入市场的承诺。</p>
</div><h2>Patent Extension for EXXUA</h2>
<div class="lb-trans"><h2>EXXUA 的专利延长</h2>
</div><p>Aytu BioScience successfully extended the EXXUA method of use patent to September 2030, enhancing its intellectual property protection. This extension is a strategic move to safeguard the product’s market potential and competitive edge.</p>
<div class="lb-trans"><p>Aytu BioScience 成功将 EXXUA 的使用方法专利延长至 2030 年 9 月，增强了其知识产权保护。这一延长是保护产品市场潜力和竞争优势的战略举措。</p>
</div><h2>Strong Cash Position</h2>
<div class="lb-trans"><h2>强劲的现金状况</h2>
</div><p>The company reported a strong cash position, with cash and cash equivalents totaling $32.6 million at the end of the quarter, up from $31 million in the previous quarter. This increase in cash reserves provides Aytu BioScience with a solid financial foundation to support its strategic initiatives.</p>
<div class="lb-trans"><p>公司报告称现金状况良好，截至本季度末现金及现金等价物总额为 3260 万美元，较上季度的 3100 万美元有所增加。这一现金储备的增加为 Aytu BioScience 提供了坚实的财务基础，以支持其战略举措。</p>
</div><h2>Decline in Pediatric Portfolio Revenue</h2>
<div class="lb-trans"><h2>儿科投资组合收入下降</h2>
</div><p>The pediatric portfolio experienced a decline in revenue, decreasing to $0.7 million from $1.3 million in the previous year. This decline was attributed to manufacturing delays and a deemphasis on marketing efforts, presenting a challenge for the company.</p>
<div class="lb-trans"><p>儿科投资组合的收入下降，从去年的 130 万美元降至 70 万美元。这一下降归因于生产延迟和对市场营销工作的重视程度降低，给公司带来了挑战。</p>
</div><h2>Gross Margin Decline</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>Aytu BioScience reported a decrease in gross margin to 66% from 72% in the previous year. When excluding a one-time rebate, the gross margin was adjusted to 65%. This decline indicates a need for the company to address cost management and efficiency.</p>
<div class="lb-trans"><p>Aytu BioScience 报告称毛利率从去年的 72% 下降至 66%。在排除一次性折扣后，毛利率调整为 65%。这一下降表明公司需要关注成本管理和效率问题。</p>
</div><h2>Regulatory Concerns on Fluoride Products</h2>
<div class="lb-trans"><h2>对氟化物产品的监管担忧</h2>
</div><p>The FDA issued a communication regarding fluoride-containing drugs, though the impact is expected to be limited. The company reported only $300,000 in revenue from fluoride products this quarter, suggesting minimal financial exposure.</p>
<div class="lb-trans"><p>FDA 就含氟药物发布了通知，尽管预计影响有限。公司本季度仅报告了 30 万美元的氟化物产品收入，表明财务风险较小。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Aytu BioScience provided forward-looking guidance with a net revenue of $13.9 million reported for fiscal 2026 Q1. The ADHD portfolio showed a 10% increase in net revenue compared to the previous year, excluding a one-time rebate benefit. The EXXUA launch remains on track for the end of calendar year 2025, with continued advancements in product manufacturing, sales force training, and marketing strategies. The company anticipates a $50 million operational expenditure for fiscal 2026, including a $10 million investment in the EXXUA launch. Aytu projects that achieving quarterly net revenue of $17.3 million will bring them to breakeven, emphasizing their confidence in EXXUA’s potential as a transformative product for treating major depressive disorder.</p>
<div class="lb-trans"><p>展望未来，Aytu BioScience 提供了前瞻性指导，预计 2026 财年第一季度净收入为 1390 万美元。ADHD 投资组合的净收入较去年增长 10%，不包括一次性折扣收益。EXXUA 的推出仍按计划在 2025 年年底前进行，产品制造、销售团队培训和市场营销策略持续取得进展。公司预计 2026 财年的运营支出为 5000 万美元，其中包括对 EXXUA 推出的 1000 万美元投资。Aytu 预计实现季度净收入 1730 万美元将使其达到盈亏平衡，强调了他们对 EXXUA 作为治疗重度抑郁症的变革性产品潜力的信心。</p>
</div><p>In summary, Aytu BioScience’s earnings call highlighted a company focused on growth through strategic product launches and managing existing challenges. The positive sentiment was driven by strong performance in the ADHD portfolio and progress towards the EXXUA launch, while declines in certain segments and regulatory concerns were acknowledged. The company’s forward-looking guidance reflects confidence in their strategic initiatives and the potential for future growth.</p>
<div class="lb-trans"><p>总之，Aytu BioScience 的财报电话会议突显了公司通过战略产品推出和管理现有挑战来专注于增长。积极的情绪源于 ADHD 投资组合的强劲表现和 EXXUA 推出的进展，同时也承认了某些细分市场的下滑和监管担忧。公司的前瞻性指导反映了对其战略举措的信心以及未来增长的潜力。</p>
</div>

Aytu BioScience 的财报电话会议突出了其增长和面临的挑战